conduritol epoxide has been researched along with Disease Models, Animal in 15 studies
conduritol epoxide: conduritol C epoxide refers to the (epi & neo)-isomers; structure
conduritol epoxide : An epoxide resulting from the epoxidation of the double bond of a conduritol.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gaucher disease is an autosomal recessive disease, caused by a lack or functional deficiency of the lysosomal enzyme, glucocerebrosidase (GCase)." | 1.42 | Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease. ( Alvarez-Fischer, D; Andreas, H; Hirsch, EC; Höglinger, GU; Höllerhage, M; Lu, L; Noelker, C; Oertel, WH; Roscher, R; Sturn, A; Vulinovic, F, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Papadopoulos, VE | 1 |
| Nikolopoulou, G | 1 |
| Antoniadou, I | 1 |
| Karachaliou, A | 1 |
| Arianoglou, G | 1 |
| Emmanouilidou, E | 1 |
| Sardi, SP | 1 |
| Stefanis, L | 1 |
| Vekrellis, K | 1 |
| Mus, L | 1 |
| Siani, F | 1 |
| Giuliano, C | 1 |
| Ghezzi, C | 1 |
| Cerri, S | 1 |
| Blandini, F | 1 |
| Kuo, CL | 1 |
| Kallemeijn, WW | 1 |
| Lelieveld, LT | 1 |
| Mirzaian, M | 1 |
| Zoutendijk, I | 1 |
| Vardi, A | 2 |
| Futerman, AH | 3 |
| Meijer, AH | 1 |
| Spaink, HP | 1 |
| Overkleeft, HS | 1 |
| Aerts, JMFG | 1 |
| Artola, M | 1 |
| Ginns, EI | 1 |
| Mak, SK | 1 |
| Ko, N | 1 |
| Karlgren, J | 1 |
| Akbarian, S | 1 |
| Chou, VP | 1 |
| Guo, Y | 1 |
| Lim, A | 1 |
| Samuelsson, S | 1 |
| LaMarca, ML | 1 |
| Vazquez-DeRose, J | 1 |
| Manning-Boğ, AB | 2 |
| Xu, YH | 3 |
| Xu, K | 1 |
| Sun, Y | 3 |
| Liou, B | 1 |
| Quinn, B | 3 |
| Li, RH | 1 |
| Xue, L | 1 |
| Zhang, W | 1 |
| Setchell, KD | 1 |
| Witte, D | 3 |
| Grabowski, GA | 4 |
| Noelker, C | 1 |
| Lu, L | 1 |
| Höllerhage, M | 1 |
| Vulinovic, F | 1 |
| Sturn, A | 1 |
| Roscher, R | 1 |
| Höglinger, GU | 1 |
| Hirsch, EC | 1 |
| Oertel, WH | 1 |
| Alvarez-Fischer, D | 1 |
| Andreas, H | 1 |
| Marshall, J | 1 |
| Bangari, DS | 1 |
| Budman, E | 1 |
| Park, H | 1 |
| Nietupski, JB | 1 |
| Allaire, A | 1 |
| Cromwell, MA | 1 |
| Wang, B | 1 |
| Leonard, JP | 1 |
| Cheng, SH | 1 |
| Zigdon, H | 1 |
| Meshcheriakova, A | 1 |
| Klein, AD | 2 |
| Yaacobi, C | 1 |
| Eilam, R | 1 |
| Kenwood, BM | 1 |
| Rahim, AA | 1 |
| Massaro, G | 1 |
| Merrill, AH | 2 |
| Vitner, EB | 1 |
| Ferreira, NS | 1 |
| Ben-Dor, S | 1 |
| Duan, J | 1 |
| Hardy, J | 1 |
| Cox, TM | 1 |
| Schüle, B | 1 |
| Langston, JW | 1 |
| Ran, H | 1 |
| Reboulet, R | 1 |
| Huelsken, J | 1 |
| Stephens, MC | 2 |
| Bernatsky, A | 1 |
| Singh, H | 2 |
| Kanfer, JN | 2 |
| Legler, G | 2 |
| Gregoriadis, G | 1 |
| Weereratne, H | 1 |
| Blair, H | 1 |
| Bull, GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia[NCT04405596] | Phase 1/Phase 2 | 15 participants (Anticipated) | Interventional | 2025-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 other studies available for conduritol epoxide and Disease Models, Animal
| Article | Year |
|---|---|
Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Brain; Disease Models, Animal; Exosomes; Glucosylceramidase; Humans; Inosi | 2018 |
Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity.
Topics: Animals; Disease Models, Animal; Enzyme Inhibitors; Glucosylceramidase; Inositol; Male; Mice; Mice, | 2019 |
In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling.
Topics: Animals; beta-Glucosidase; Brain; Cyclohexanols; Disease Models, Animal; Enzyme Assays; Glucosylcera | 2019 |
Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction.
Topics: alpha-Synuclein; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Evoked Potentials, Moto | 2014 |
Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice.
Topics: alpha-Synuclein; Amyloid beta-Protein Precursor; Animals; beta-Glucosidase; Cells, Cultured; Cerebra | 2014 |
Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease.
Topics: 1-Deoxynojirimycin; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Cells, | 2015 |
CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.
Topics: Administration, Oral; Animals; Carbamates; Central Nervous System; Disease Models, Animal; Enzyme In | 2016 |
Delineating pathological pathways in a chemically induced mouse model of Gaucher disease.
Topics: Animals; Disease Models, Animal; Gaucher Disease; Gene Expression Profiling; Inositol; Mice | 2016 |
Identification of Modifier Genes in a Mouse Model of Gaucher Disease.
Topics: Animals; Base Sequence; Disease Models, Animal; Gaucher Disease; Genes, Modifier; Genome-Wide Associ | 2016 |
Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Cell Differentiation; Disease Models, Animal; Dose-R | 2009 |
Accumulation and distribution of α-synuclein and ubiquitin in the CNS of Gaucher disease mouse models.
Topics: Age Factors; alpha-Synuclein; Animals; beta-Glucosidase; Brain; Disease Models, Animal; Gaucher Dise | 2011 |
Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels.
Topics: Animals; Central Nervous System; Cytokines; Disease Models, Animal; Disease Progression; Female; Gau | 2008 |
Distribution of conduritol B epoxide in the animal model for Gaucher's disease (Gaucher mouse).
Topics: Animals; beta-Glucosidase; Blood-Brain Barrier; Disease Models, Animal; Gaucher Disease; Glucosidase | 1981 |
The Gaucher mouse.
Topics: Acid Phosphatase; Animals; beta-Glucosidase; Brain; Cerebrosides; Disease Models, Animal; Galactosyl | 1982 |
Liposomes in Gaucher type I disease: use in enzyme therapy and the creation of an animal model.
Topics: Adult; Animals; beta-Glucosidase; Disease Models, Animal; Female; Gaucher Disease; Glucosidases; Glu | 1982 |